International Stem Cell Corp
International Stem Cell Corporation, a clinical stage biotechnology company, focuses on the development of therapeutic and biomedical products in the United States, Asia, Europe, and internationally. It develops ISC-hpNSC, a neural stem cell program that has completed the Phase I clinical trial for the treatment of Parkinson's disease, as well as for treating stroke, traumatic brain injury, and A… Read more
International Stem Cell Corp (ISCO) - Total Assets
Latest total assets as of September 2025: $5.28 Million USD
Based on the latest financial reports, International Stem Cell Corp (ISCO) holds total assets worth $5.28 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
International Stem Cell Corp - Total Assets Trend (2012–2024)
This chart illustrates how International Stem Cell Corp’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
International Stem Cell Corp - Asset Composition Analysis
Current Asset Composition (December 2024)
International Stem Cell Corp's total assets of $5.28 Million consist of 68.8% current assets and 31.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 23.8% |
| Accounts Receivable | $1.06 Million | 20.5% |
| Inventory | $1.15 Million | 22.2% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $721.00K | 13.9% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2012–2024)
This chart illustrates how International Stem Cell Corp's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: International Stem Cell Corp's current assets represent 68.8% of total assets in 2024, an increase from 0.0% in 2012.
- Cash Position: Cash and equivalents constituted 23.8% of total assets in 2024, up from 12.2% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 13.0% of total assets, a decrease from 30.0% in 2012.
- Asset Diversification: The largest asset category is inventory at 22.2% of total assets.
International Stem Cell Corp Competitors by Total Assets
Key competitors of International Stem Cell Corp based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
International Stem Cell Corp - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - International Stem Cell Corp generates 1.76x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - International Stem Cell Corp is currently not profitable relative to its asset base.
International Stem Cell Corp - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.80 | 0.74 | 1.47 |
| Quick Ratio | 0.46 | 0.45 | 0.85 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-921.00K | $ -1.23 Million | $ 700.00K |
International Stem Cell Corp - Advanced Valuation Insights
This section examines the relationship between International Stem Cell Corp's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.09 |
| Asset Growth Rate (YoY) | -4.0% |
| Total Assets | $5.17 Million |
| Market Capitalization | $444.06K USD |
Valuation Analysis
Below Book Valuation: The market values International Stem Cell Corp's assets below their book value (0.09 x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: International Stem Cell Corp's assets decreased by 4.0% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for International Stem Cell Corp (2012–2024)
The table below shows the annual total assets of International Stem Cell Corp from 2012 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $5.17 Million | -4.03% |
| 2023-12-31 | $5.39 Million | +4.97% |
| 2022-12-31 | $5.13 Million | +3.82% |
| 2021-12-31 | $4.95 Million | -6.45% |
| 2020-12-31 | $5.29 Million | -20.14% |
| 2019-12-31 | $6.62 Million | -15.08% |
| 2018-12-31 | $7.80 Million | +13.58% |
| 2017-12-31 | $6.86 Million | -2.57% |
| 2016-12-31 | $7.04 Million | -1.30% |
| 2015-12-31 | $7.14 Million | -0.57% |
| 2014-12-31 | $7.18 Million | -7.24% |
| 2013-12-31 | $7.74 Million | +44.12% |
| 2012-12-31 | $5.37 Million | -- |